Research Output per year
Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit
Heart Failure
Medicine & Life Sciences
Atrial Fibrillation
Medicine & Life Sciences
Echocardiography
Medicine & Life Sciences
Myocardial Infarction
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Coronary Artery Disease
Medicine & Life Sciences
Left Ventricular Dysfunction
Medicine & Life Sciences
Cardiovascular Diseases
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Profiles
Research Output 1965 2019
ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons
Patel, M. R., Calhoon, J. H., Dehmer, G. J., Grantham, J. A., Maddox, T. M., Maron, D. J., Smith, P. K., Wolk, M. J., Patel, M. R., Dehmer, G. J., Smith, P. K., Blankenship, J. C., Bove, A. A., Bradley, S. M., Dean, L. S., Duffy, P. L., Ferguson, T. B., Grover, F. L., Guyton, R. A., Hlatky, M. A. & 27 others, Mar 1 2019, In : Journal of Thoracic and Cardiovascular Surgery. 157, 3, p. e131-e161Research output: Contribution to journal › Article
Advisory Committees
Percutaneous Coronary Intervention
Myocardial Ischemia
Tomography
Acetyltransferase p300 inhibitor reverses hypertension-induced cardiac fibrosis.
Rai, R., Sun, T., Ramirez, V., Lux, E., Eren, M., Vaughan, DE. & Ghosh, AK., Feb 1 2019, In : J Cell Mol Med.. doi: 10.1111/jcmm.14162., [Epub ahead of print]Research output: Contribution to journal › Article
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial
Virani, S. S., Akeroyd, J. M., Nambi, V., Michos, E. D., Morris, P. B., Nasir, K., Smith, S. C., Stone, N. J., Petersen, L. A. & Ballantyne, C. M., Jan 15 2019, In : Circulation. 139, 3, p. 410-412 3 p.Research output: Contribution to journal › Letter
Cholesterol
Clinical Trials
Costs and Cost Analysis
Proprotein Convertase 9
Grants 1999 2023
The role of plasminogen activator inhibitor -1 (PAI-1) in chronic kidney disease(CKD)-associated cardiac hypertrophy
1/1/19 → 12/31/20
Project: Research project
Plasminogen Activator Inhibitor 1
Cardiomegaly
Chronic Renal Insufficiency
Hypertrophy
Transgenic Mice
Prot#1245.110: EMPORER - A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF)
Quintiles, Inc., Boehringer Ingelheim Pharmaceuticals, Inc.
11/30/18 → 11/30/21
Project: Research project
NU Site: CAPriCORN - Chicago Area Patient-Centered Outcomes Research Network
People-Centered Research Foundation, Patient-Centered Outcomes Research Institute
11/1/18 → 9/30/20
Project: Research project
Patient Outcome Assessment
Health
Research
Health Services Research